Concentric Capital Strategies LP Increases Stake in Danaher Co. (NYSE:DHR)

Concentric Capital Strategies LP grew its position in Danaher Co. (NYSE:DHR - Free Report) by 203.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,182 shares of the conglomerate's stock after buying an additional 4,815 shares during the period. Concentric Capital Strategies LP's holdings in Danaher were worth $1,997,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DHR. CarsonAllaria Wealth Management Ltd. bought a new position in Danaher during the second quarter valued at approximately $25,000. nVerses Capital LLC purchased a new position in shares of Danaher in the 2nd quarter worth $25,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Danaher in the 3rd quarter worth $39,000. MidAtlantic Capital Management Inc. purchased a new stake in Danaher during the third quarter valued at $40,000. Finally, FSA Wealth Management LLC bought a new position in Danaher in the third quarter valued at about $50,000. Institutional investors own 79.05% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. TD Cowen upped their price target on shares of Danaher from $310.00 to $315.00 and gave the company a "buy" rating in a research report on Wednesday, October 23rd. StockNews.com upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research report on Wednesday, November 27th. UBS Group cut their price objective on shares of Danaher from $309.00 to $305.00 and set a "buy" rating for the company in a research report on Wednesday, October 23rd. Evercore ISI raised their target price on Danaher from $275.00 to $278.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Finally, Stifel Nicolaus boosted their price target on Danaher from $250.00 to $265.00 and gave the company a "hold" rating in a report on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, Danaher has a consensus rating of "Moderate Buy" and an average target price of $287.16.

Danaher Price Performance

Shares of NYSE:DHR traded down $0.60 during mid-day trading on Tuesday, reaching $240.69. The stock had a trading volume of 1,125,523 shares, compared to its average volume of 2,753,081. The company has a market cap of $173.85 billion, a P/E ratio of 46.04, a price-to-earnings-growth ratio of 4.41 and a beta of 0.83. The business's 50 day moving average price is $254.59 and its 200 day moving average price is $259.41. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 1 year low of $215.68 and a 1 year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts' consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the company earned $2.02 EPS. The company's quarterly revenue was up 3.1% compared to the same quarter last year. Research analysts expect that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher's dividend payout ratio is currently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.